EMERGENCY:For an adolescent with sudden episodes of extreme sleepiness lasting days to weeks —call040-46324365immediately — 24 hours, 7 days— 24/7
Kleine-Levin Syndrome in Hyderabad: The Adolescent Who Disappears Into Sleep for Weeks at a Time — and Returns Completely Normal
Expert ICSD-3 diagnosis, EEG and MRI workup, and lithium prophylaxis for Kleine-Levin syndrome at KIMS Neuroscience, Secunderabad, Hyderabad.
Kleine-Levin syndrome is a rare, recurrent sleep disorder characterised by episodes of extreme hypersomnia — sleeping 15-20 hours per day — lasting days to several weeks, accompanied by cognitive disturbance (derealization, confusion), and behavioural changes (hyperphagia, hypersexuality). Between episodes, the person returns to complete normality. KLS predominantly affects adolescent males (male:female 3:1, onset age 10-20). It is self-limiting: episodes become fewer and shorter over 8-12 years and then stop completely in most patients. The likely mechanism: immune-mediated thalamic-hypothalamic dysfunction triggered by viral illness (72% of episodes preceded by infection), producing a transient hypometabolic state documented on SPECT and PET. KLS is not depression, drug use, or malingering — it is a neurological condition with a diagnostic pattern.
- What it is
- Episodic, recurrent bouts of 15-20h/day sleep typically lasting 1-3 weeks (median ~10 days), with completely normal sleep, mood and cognitive function between episodes, with derealization and confusion when awake, hyperphagia. Complete normality between episodes. Predominantly adolescent males.
- The diagnostic key
- Complete inter-episode normality. A teenager completely normal between episodes, then sleeping 20h/day for 2 weeks, then completely normal again — has KLS until proven otherwise.
- Not depression, not drugs
- KLS episodes are preceded by viral illness (72%), produce specific EEG changes (delta-theta slowing), and resolve with a switch-like termination. Drug screen, EEG, and clinical pattern distinguish from other causes.
- The good news: self-limiting
- Episodes become fewer and shorter over 8-12 years. Most patients are episode-free by late 20s to early 30s. Median duration: 14 years (males), 8 years (females). No permanent cognitive deficit between episodes.
- Lithium prophylaxis
- 300-600mg twice daily. 40-60% reduction in episode frequency in some patients. Requires monitoring: lithium levels (target 0.6-1.0 mEq/L) · 6-monthly TSH (hypothyroidism risk) · Annual eGFR.
- Educational support at KIMS
- Formal medical letter for school/university examination boards enabling deferred examinations, extended deadlines, and individual educational plans. Multiple studies confirm no cumulative cognitive deficit between episodes.
- Contact KIMS
- 040-44885000 · ICSD-3 diagnostic workup with EEG and MRI · Lithium prophylaxis with monitoring · School/university documentation.
| Fact | Details |
|---|---|
| Definition | Episodic, recurrent hypersomnia (15-20h/day) · Derealization and confusion when awake · Hyperphagia/hypersexuality in episodes · COMPLETE normality between episodes |
| Episode duration | Typically 1-3 weeks (median ~10 days) · Onset and termination are abrupt · Episodes recur after intervals that are often months long |
| Interictal periods | Completely normal sleep, mood and cognitive function · No residual sleepiness, cognitive impairment or mood disorder — the defining diagnostic feature |
| Epidemiology | 1-5 per million prevalence · Adolescent males (3:1) · Onset age 10-20 · Significantly underdiagnosed in India · Often attributed to drugs or depression |
| Trigger | Viral URTI (72% of episodes) · Fever · Alcohol · Sleep deprivation · Stress · Menstruation (some female patients) |
| Diagnosis (ICSD-3) | 2+ episodes of hypersomnia lasting 2 days-5 weeks · At least one cognitive or behavioural symptom · Complete normality between episodes · Not better explained by another condition |
| EEG in episode | Generalised delta-theta slowing · Consistent with diffuse thalamic/cortical hypometabolism · Normal between episodes |
| Prophylaxis | Lithium (300-600mg BD) · 40-60% episode reduction · Monitor lithium levels, TSH (6-monthly), eGFR (annual) · Sodium valproate alternative · Carbamazepine (weaker evidence) |
| Prognosis | Self-limiting in majority · Median duration 14 years (males), 8 years (females) · No permanent cognitive deficit · Does not progress to other neurological conditions |
About This Condition
The Month That Disappeared
A 17-year-old student in Hyderabad is brought to KIMS by his parents, who are frantic. Three weeks ago, one week after a mild upper respiratory tract infection, he began sleeping 18–20 hours per day. He wakes only to eat (consuming large amounts of food), briefly use the bathroom, and then returns to sleep. When awake, he is not himself: he answers questions with single words, says things that do not make sense, and describes everything around him as feeling unreal, like a dream. He does not know what day it is. He is not distressed by this — he seems dull and indifferent rather than anxious. He has missed three weeks of school.
Before this episode, he was a bright, engaged student — his teachers describe him as one of the best in his class. His parents confirm that he was completely normal until 3 days before the hypersomnia started. This is his second episode; the first, 8 months ago, lasted 10 days and was attributed to a viral illness with prolonged recovery.
At KIMS, the clinical picture is immediately recognised. The combination of recurrent episodes of hypersomnia (sleeping 15–20 hours per day), with accompanying cognitive disturbance (derealization, confusion, slowed thinking), in an adolescent male, preceded by a viral illness, with complete normality between episodes = Kleine-Levin syndrome. EEG during the episode: generalised background slowing (delta-theta predominant), consistent with a diffuse cortical/thalamic hypometabolic state. MRI brain: normal. Metabolic screen (thyroid, glucose, ammonia, drug screen): all normal. CSF: normal.
The family is counselled: Kleine-Levin syndrome is a recognised neurological condition. This episode will resolve, as the first one did. Long-term, most KLS patients have fewer and shorter episodes over the years, and most stop entirely within 8–12 years. Lithium carbonate is discussed as a prophylactic treatment that reduces episode frequency and severity in some patients. He is started on lithium 300mg twice daily after the current episode resolves, with monitoring of lithium levels and thyroid function. At 4-day follow-up: he has woken. He is completely normal — the confusion, derealization, and hypersomnia have resolved as if a switch was turned off. He has no memory of the past 3 weeks except for fragments. He sits the examination he missed in a deferred session.
Book a Consultation
Speak directly with our sleep specialist team. ICSD-3 KLS workup with EEG and MRI. Monday to Saturday.
040-44885000Emergency line: 040-46324365Quick Facts about KLS
The essential context: what KLS is, who is affected, the suspected mechanism, and the hallmark inter-episode normality.
What it is
Kleine-Levin syndrome (KLS) is defined by episodic, recurrent bouts of hypersomnia — sleeping 15 to 20 or more hours per day — typically lasting 1 to 3 weeks (median approximately 10 days), interspersed with completely normal sleep, mood, and cognitive function during interictal periods. During episodes, the affected person cannot be kept fully awake, is cognitively impaired (confused, slow, derealized), and behaviorally altered. Between episodes — which may be months apart — the person returns to their completely normal baseline. KLS is not a psychological condition, a drug problem, or malingering — it is a neurological disorder with a characteristic pattern that is diagnostic once recognised.
Who is affected
KLS predominantly affects adolescent males (male:female ratio approximately 3:1), with the first episode typically occurring between ages 10 and 20. It is rare — prevalence is estimated at approximately 1–5 per million — but because it primarily strikes during the critical years of secondary and higher education, its educational and social impact is disproportionate to its rarity. In India, KLS is almost certainly underdiagnosed because the episodic hypersomnia is often attributed to depression, drug use, or malingering.
What causes KLS
The exact cause is unknown. Current evidence points to immune-mediated hypothalamic-thalamic dysfunction: the thalamus — which regulates arousal, consciousness, and sensory gating — shows functional hypometabolism during KLS episodes on SPECT and PET imaging. Proposed triggers: upper respiratory tract infections (approximately 72% of episodes are preceded by viral illness), stress, alcohol consumption (even modest amounts), and sleep deprivation. The most likely mechanism: an autoimmune or para-infectious process temporarily disrupts thalamic function in genetically susceptible individuals. The condition is self-limiting in most cases — episodes become less frequent and shorter over 8–12 years and then stop.
The complete normality between episodes
One of the most diagnostically important and clinically perplexing features of KLS: between episodes, the patient is completely normal cognitively, behaviourally, and neurologically. There is no residual sleepiness, no cognitive impairment, and no evidence of depression or other psychiatric disorder. The episodic nature — completely well, then suddenly sleeping 20 hours per day for 2 weeks, then completely well again — is the hallmark. This complete inter-episode normality distinguishes KLS from depression (where low mood is persistent), hypothyroidism (constant fatigue), and narcolepsy (daily EDS).
Clinical Features of KLS Episodes
KLS episodes have a recognisable pattern. The cluster of features — and the complete normality between episodes — is what makes the diagnosis.
Hypersomnia — the defining feature of KLS episodes
During a KLS episode, the patient sleeps 15–20 hours per day and cannot be kept fully awake for normal social interaction. When roused, they typically return to sleep within minutes. This is not normal sleepiness or depression — it is a state of dramatically reduced arousal from thalamic dysfunction. Parents describe their child as "impossible to wake," "like a different person," and "not really there even when their eyes are open."
Cognitive disturbance — derealization and confusion
When awake during an episode, KLS patients describe the world as feeling unreal (derealization: "everything looks like a dream," "like I am watching through glass"), are confused and disoriented, respond slowly and with minimal language, and have profound short-term memory impairment during the episode. They may have no memory of the episode on recovery. The degree of cognitive impairment is sometimes severe enough that the patient cannot safely manage basic activities.
Behavioral features — hyperphagia, hypersexuality, megaphagia
Many KLS patients have episodic hyperphagia (compulsive, indiscriminate eating of large quantities of food, sometimes unusual food combinations) during episodes. A smaller proportion have hypersexuality (inappropriate, disinhibited sexual behaviour or speech, more common in males). These behaviours are completely out of character for the patient and resolve completely with the episode. They reflect the hypothalamic-limbic dysfunction of KLS affecting appetite and impulse control circuits.
Episode triggers
Recognised episode triggers in KLS: upper respiratory tract infections (the most common, present before approximately 72% of episodes); fever; alcohol consumption (even small amounts can trigger an episode in KLS patients); physical or emotional stress; sleep deprivation; and in some female patients, menstruation. Patients and families at KIMS are counselled to avoid alcohol completely and to manage infections promptly with rest and paracetamol.
The complete normality between episodes
The inter-episode period in KLS is completely normal. The patient has normal cognitive function, normal behaviour, normal sleep, and no mood disorder. This complete normality is one of the most important diagnostic features and distinguishes KLS from all other causes of hypersomnia. A teenager who is completely normal between episodes and then suddenly sleeping 20 hours per day again has KLS until proven otherwise.
Diagnosis at KIMS
Diagnosis at KIMS
KLS is a clinical diagnosis based on ICSD-3 (International Classification of Sleep Disorders, 3rd edition) criteria. No single test confirms KLS; the diagnosis is made from the clinical pattern, with investigations used to exclude other causes.
Recurrent episodes of hypersomnia
At least 2 episodes of excessive sleepiness lasting 2 days to 5 weeks. The episodic pattern — sudden onset, prolonged hypersomnia, then full resolution — is the central diagnostic feature.
Cognitive or behavioral symptoms during episodes
At least one of: cognitive dysfunction (derealization, confusion, amnesia); behavioral change (hyperphagia, hypersexuality, irritability); mood change. Documented during the episode itself, ideally with a brief neuropsychological assessment.
Complete normality between episodes
No hypersomnia, cognitive impairment, or behavioral change between episodes. Confirmed with full neuropsychological battery (normal); repeated EEG (normal); and a structured review of the episode pattern with the patient and family.
Not better explained by another condition
Encephalitis, bipolar disorder, depression, drug use, or other medical causes excluded. Investigations at KIMS during an episode: EEG (generalised slowing, supporting thalamic/cortical hypometabolism); MRI brain (usually normal; may show thalamic signal change in some cases); metabolic screen (thyroid, glucose, ammonia, drug screen, viral serology) to exclude secondary causes.
Treatment
Treatment and Management at KIMS
KLS management combines acute episode safety, prophylactic treatment to reduce future episodes, and structured family and school support.
Acute Episode Management
There is no established treatment that reliably shortens an acute KLS episode. Approaches tried with variable success: amantadine (100–200mg daily — some reports of episode shortening); stimulants (modafinil, methylphenidate — may partially improve wakefulness during an episode); clarithromycin (an antibiotic that acts as a GABA-A receptor blocker and has been reported to hasten recovery in isolated cases). None has Level 1 evidence. At KIMS, the acute management focuses on: safety (supervision, no driving, no hazardous activities); adequate nutrition and hydration (ensuring the patient eats and drinks when briefly awake); school/work documentation; and reassurance to the family.
Prophylactic Treatment
Lithium carbonate (300–600mg twice daily): the most frequently used prophylactic agent for KLS. Retrospective studies show approximately 40–60% reduction in episode frequency and severity in some patients. Not universally effective. Requires monitoring of serum lithium levels (target 0.6–1.0 mEq/L), thyroid function (lithium causes hypothyroidism in long-term use), and renal function. At KIMS, lithium is started after the second or third episode when the episode pattern is established. Sodium valproate is an alternative to lithium for prophylaxis; some evidence for episode reduction. Carbamazepine is used in some centres; evidence weaker than lithium.
Family and School Support
KLS has profound effects on education — a student can miss 2–3 weeks of school per episode, with 2–4 episodes per year in some cases. At KIMS: formal medical documentation is provided for school or university examination boards, enabling deferred examinations, extended coursework deadlines, and individual educational plans. Family counselling addresses the distress, disruption, and sometimes catastrophising that KLS produces — particularly when family members attribute the episodes to drug use or laziness before the diagnosis is made.
Related Conditions
Kleine-Levin Syndrome belongs to the family of sleep disorders managed at KIMS:
FAQs
Frequently Asked Questions
The adolescent who has been sleeping 20 hours a day for 2 weeks and was told it was drugs or laziness. The student who has missed 6 weeks of school this year and does not know why.
Kleine-Levin syndrome is diagnosable at KIMS with EEG and the ICSD-3 clinical criteria, managed with lithium prophylaxis, and documented for school examination boards. And it resolves. Call 040-44885000.
International enquiries: info@kimsneurosciences.com